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Purpose: The capacity of nadir CA-125 levels to predict the prognosis of epithelial ovarian cancer remains
controversial. This study aimed to explore whether the nadir CA-125 serum levels could predict the durations of
overall survival (OS) and progression free survival (PFS) in patients with high-grade serous ovarian cancer (HG-SOC)
from the USA and PRC.
Materials and methods: A total of 616 HG-SOC patients from the MD Anderson Cancer Center (MDACC, USA)
between 1990 and 2011 were retrospectively analyzed. The results of 262 cases from the Jiangsu Institute of Cancer
Research (JICR, PRC) between 1992 and 2011 were used to validate the MDACC data. The CA-125
immunohistochemistry assay was performed on 280 tissue specimens. The Cox proportional hazards model and the
log-rank test were used to assess the associations between the clinicopathological characteristics and duration of
survival.
Results: The nadir CA-125 level was an independent predictor of OS and PFS (p < 0.01 for both) in the MDACC
patients. Lower nadir CA-125 levels (≤10 U/mL) were associated with longer OS and PFS (median: 61.2 and
16.8 months with 95% CI: 52.0–72.4 and 14.0–19.6 months, respectively) than their counterparts with shorter OS and
PFS (median: 49.2 and 10.5 months with 95% CI: 41.7–56.7 and 6.9–14.1 months, respectively). The nadir CA-125
levels in JICR patients were similarly independent when predicting the OS and PFS (p < 0.01 for both). Nadir CA-125
levels less than or equal to 10 U/mL were associated with longer OS and PFS (median: 59.9 and 15.5 months with
95% CI: 49.7–70.1 and 10.6–20.4 months, respectively), as compared with those more than 10 U/mL (median: 42.0
and 9.0 months with 95% CI: 34.4–49.7 and 6.6–11.2 months, respectively). Baseline serum CA-125 levels, but not
the CA-125 expression in tissues, were associated with the OS and PFS of HG-SOC patients in the MDACC and JICR
groups. However, these values were not independent. Nadir CA-125 levels were not associated with the tumor
burden based on second-look surgery (p = 0.09). Patients who achieved a pathologic complete response had longer
OS and PFS (median: 73.7 and 20.7 months with 95% CI: 63.7–83.7 and 9.5–31.9 months, respectively) than those
with residual tumors (median: 34.6 and 10.6 months with 95% CI: 6.9–62.3 and 4.9–16.3 months, respectively).
Conclusions: The nadir CA-125 level was an independent predictor of OS and PFS in HG-SOC patients. Further
prospective studies are required to clinically optimize the chances for a complete clinical response of HG-SOC cases
with higher CA-125 levels (>10 U/mL) at the end of primary treatment.
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Table 1 Patient characteristics of the study population
Characteristic Percentage (%)/median (range)
MDACC (n = 616) JICR (n = 262)
Age (years) 60.3 (20–92) 62.1 (22–85)
Baseline CA-125 level (U/mL) 800 (7–33423) 927 (5–24880)
Nadir CA-125 level (U/mL) 10 (4–35) 10 (2–35)
Ethnic group
White 481(78.1) 0 (0.0)
Black 35 (5.7) 0 (0.0)
Hispanic 76 (12.3) 0 (0.0)
Eastern Asian 16 (2.6) 262 (100.0)
Others * 8 (1.3) 0 (0.0)
Surgical residual
<1 cm 366 (59.4) 142 (54.2)
1–2 cm 19 (3.1) 7 (2.7)
>2 cm 154 (25.0) 76 (29.0)
Unknown 77 (12.5) 37 (14.1)
FIGO stage
I 49 (8.0) 21 (8.0)
II 36 (5.8) 15 (5.7)
III 410 (66.6) 171 (65.3)
IV 125 (20.3) 52 (19.8)
Unknown 4 (0.6) 2 (0.8)
Neo-adjuvant chemotherapy 133 (21.2) 186 (71.0)
FIGO the International Federation of Gynecology and Obstetrics.
Others* including 5 Middle Eastern, and 3 Indian cases.
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Ovarian cancer is the most frequent lethal gynecological
cancer in North America and Western Europe; it ranks
fifth among the cancers that cause the highest mortality
in Chinese women [1-3]. Approximately 22,240 new
cases of ovarian cancer in the United States were diag-
nosed in 2013; 14,030 deaths were caused by the disease
in the same year [1]. Despite great progress in the man-
agement of ovarian cancer, the mortality rate of ovarian
cancer has insignificantly decreased in the past two de-
cades [4]. These data emphasize the need to identify
prognostic indicators and more efficient therapeutic
strategies for epithelial ovarian cancer (EOC), at least for
the high-risk subgroup.
Epithelial ovarian cancer does not usually appear as a
single entity but represents a heterogeneous group of dis-
tinct disease types, including the serous, endometrioid, mu-
cinous, clear-cell, and undifferentiated carcinomas, as well
as in malignant Brenner and mixed mesodermal tumors
[5]. We have previously described the different origins,
molecular characteristics, and prognosis of high-grade
serous ovarian carcinoma (HG-SOC) and all other EOC
subtypes [6]. HG-SOC usually represents the arche-
typical EOC; the high fatality rate of EOC is attributed
to HG-SOCs [7].
The CA-125 antigen was developed in the late 1970s
and was first reported in 1981 by Bast et al. from mice
immunized with the OVCA433 human serous ovarian
cancer cell line [8]. This antigen has been evaluated for
detecting, monitoring, distinguishing, and observing
ovarian or peritoneal malignances [9,10]. Attempts have
been made to predict survival using the CA-125 level
and also showed that different EOC subtypes have dis-
tinct CA-125 levels and prognosis [11,12]. Furthermore,
different studies in this research area used distinct recruit-
ment standards. Thus, patients ranged from those with
complete clinical response (CCR), as well as persisting
and/or progressing disease, at the end of first line treat-
ment to those with a recurrent disease after a PFS that
varied from weeks to years. Most of these studies focused
on advanced-stage EOC but not on its pathologic type
[13-16]. Pathological heterogeneity of EOC was reported
to influence the efficiency of the CA-125 level as an in-
dicator in a single-institution study [12]. Type II EOC
cases, including HG-SOC, were more conclusive than
type I cases when CA-125 was used as a prognosis indi-
cator. Therefore, the evaluation of nadir CA-125 as a
prognosis indicator in a large HG-SOC subpopulation is
urgently needed.
In the present study, we retrospectively analyzed clinico-
pathological factors, including CA-125 in patients with
HG-SOC who were treated at the MD Anderson Cancer
Center (MDACC, USA). We also recruited HG-SOC cases




Between January 1, 1990, and February 14, 2011, 616
HG-SOC patients who underwent primary treatment at
the MDACC were identified. A total of 80 cases with
second-look surgery were available for further study,
with detailed exploration information and known CA-125
levels at second-look. Forty-three cases demonstrated a
pathological complete response (pCR).
A total of 262 HG-SOC patients from JICR were
recruited between January 1, 1992 and December 31, 2011
for validation of the MDACC data. This retrospective
study was approved by the Institutional Review Boards
of MDACC and JICR. Written informed consent was
obtained from the patient for publication of this report
and any accompanying images.
Clinicopathological characteristics
Clinicopathological data was collected using chart re-
view. Data included the age, ethnicity, physical examin-
ation, family history, obstetric history, history of present
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debulking, adjuvant chemotherapy regime, courses of ad-
juvant chemotherapy, clinical response, second-look oper-
ation findings, ascite volume, date of death (if applicable),
time of recurrence, and subsequent management [17].
Overall survival (OS) is defined as the time interval from
diagnosis until death, or until last follow-up examination
of patients who are still alive. Progression free survival
(PFS) is the length of time during and after primary treat-
ment wherein the patient’s condition does not worsen.
Clinical response and progress were defined according to
the Response Evaluation Criteria in Solid Tumors, also
known as RECIST, standards [18]. The pathology of all pa-
tients was initially reviewed by pathologists from MDACC
(J. Liu and J. Zhang) and JICR (X. Y. Xu and N. Hou).CA-125 assay
The serum CA-125 concentration was determined using a
commercially available Roche immunoassay assay system
at the MDACC and JICR clinical laboratories. In clinical
practice, a reference value of 35 U/mL is generally consid-
ered the upper limit of the normal range.Table 2 Univariate analysis of survival-related characteristics
Variable PFS (OR, 95% CI)
MDACC
FIGO stage
I 1.00 (reference) 1.00 (r
II 1.11 (0.44–2.81) 1.27 (0
III 2.66 (1.25–5.66) 4.19 (1
IV 3.03 (1.37–6.70) 6.57 (3
Ascites
No 1.00 (reference) 1.00 (r
Yes 1.73 (1.22–2.47) 1.93 (1
Residual tumors
No 1.00 (reference) 1.00 (r
Yes 1.54 (1.10–2.14) 1.68 (1
Neo-chemotherapy
Yes 1.00 (reference) 1.00 (r
No 1.38 (1.01–1.95) 1.45 (1
Chemotherapy, including paclitaxel
Yes 1.00 (reference) 1.00 (r
No 1.01 (0.82–1.47) 1.12 (1
CA-125, decreasing kinetics
≥1/32 1.00 (reference) 1.00 (r
<1/32 1.12 (1.06–1.47) 1.50 (1
Baseline CA-125 1.02 (1.01–1.06) 1.03 (1
CA-125 level at relapse 1.01 (1.00–1.01) 1.01 (1
Nadir CA-125 1.04 (1.02–1.08) 1.06 (1Tissue samples for the CA-125 immunohistochemical
assay were obtained from MDACC (228) and JICR (62)
between 1990 and 2001. CA-125 staining was semi-
quantitatively assessed in accordance with a previously
described standard [19]. The microarray slides of the
immunostained tissue were scored using computerized
digital analysis (Ariol SL-50; Applied Imaging, California).
For the statistical analysis, all cases demonstrating the
total integrated optical density (mean ± SE) were grouped
together based on a scale of 0 to 3.
We defined the baseline CA-125 level as the level at the
start of diagnosis. The nadir CA-125 level includes the ob-
served values during the two-week interval after the first
evaluation. The CA-125 level during a relapse includes
those observed in the two-week interval after the relapse.
The relationship between the nadir CA-125 level and the
duration of survival was explored: (1) as a continuous vari-
able in the Cox regression analysis and (2) as a dichotom-
ous variable around the median in the log-rank test.
Statistical analysis
The Cox proportional hazards model was used to assess
the association between survival and the absolute serumin HG-SOCs
OS (OR, 95% CI)
JICR MDACC JICR
eference) 1.00 (reference) 1.00 (reference)
.63–3.95) 1.31 (0.45–3.77) 1.62 (0.65–3.99)
.97–9.64) 3.65 (1.56–9.17) 4.79 (2.26–10.14)
.05–13.69) 5.38 (2.20–13.20) 7.03 (3.28–15.05)
eference) 1.00 (reference) 1.00 (reference)
.52–2.42) 1.92 (1.42–2.60) 2.04 (1.61–2.58)
eference) 1.00 (reference) 1.00 (reference)
.15–2.40) 1.99 (1.63–2.63) 2.10 (1.67–2.56)
eference) 1.00 (reference) 1.00 (reference)
.14–1.78) 1.33 (0.40–3.56) 1.12 (0.84–1.60)
eference) 1.00 (reference) 1.00 (reference)
.00–1.44) 1.30 (0.41–4.10) 1.18 (0.80–1.63)
eference) 1.00 (reference) 1.00 (reference)
.23–1.85) 1.17 (0.62–2.27) 1.09 (0.67–2.21)
.01–1.06) 1.03 (1.01–1.05) 1.06 (1.02–1.10)
.00–1.02) 1.01 (1.00–1.01) 1.01 (1.00–1.13)
.02–1.09) 1.02 (1.01–1.04) 1.04 (1.01–1.07)
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wise regression techniques were used to build multivari-
ate models, with a cut-off of 0.15 to remain in the
model. Associations were regarded as significant if the
two sides had p < 0.05. The Kaplan–Meier estimates
were calculated and compared using the log-rank test
for OS and PFS values stratified by various prognostic
factor categories. All analyses were conducted using SAS
(version 9.0; SAS Institute, Carey, North Carolina, USA).Results
Patient characteristics
A total of 616 HG-SOCs from MDACC and 262 cases
from JICR were recruited in this study. The clinico-
pathological characteristics of the patients are described
in Table 1. The median follow-up of the survivors
was 38 months (interquartile range, 20.2 months to
73.0 months) for the patients from MDACC. The
median follow up of the survivors was 35 months
(interquartile range, 18.4 months to 66.2 months) for
the patients from JICR.Table 3 Multivariate analysis of survival-related characteristic
Variable PFS (OR, 95% CI)
MDACC
FIGO stage
I 1.00 (reference) 1.00 (
II 1.07 (0.35–3.14) 1.22 (
III 1.83 (1.18–4.29) 3.24 (
IV 2.26 (1.24–5.25) 4.37 (
Ascites
No 1.00 (reference) 1.00 (
Yes 1.40 (1.16–2.03) 1.85 (
Residual tumors
No 1.00 (reference) 1.00 (
Yes 8.54 (4.24–16.82) 9.12 (
Neo-chemotherapy
Yes 1.00 (reference) 1.00 (
No 1.28 (0.88–2.24) 1.27 (
Chemotherapy, including paclitaxel
Yes 1.00 (reference) 1.00 (
No 1.00 (0.61–2.62) 1.07 (
CA-125, decreasing kinetics
≥1/32 1.00 (reference) 1.00 (
<1/32 1.06 (0.84–1.83) 1.37 (
Baseline CA-125 1.00 (0.98–1.02) 1.00 (
CA-125 level at relapse 1.00 (0.97–1.04) 1.00 (
Nadir CA-125 1.02 (1.00–1.04) 1.02 (Nadir CA-125 level was a prognosis indicator in HG-SOCs
The median baseline CA-125 level was 800 U/mL
(interquartile range: 322 U/mL to 2871 U/mL) and the
median nadir CA-125 level was 10 U/mL (range: 4 U/mL
to 35 U/mL) in MDACC HG-SOCs. The median baseline
and nadir CA-125 levels in JICR cases were 927 U/mL
(interquartile range: 428 U/mL to 3266 U/mL) and 10 U/mL
(range: 2 U/mL to 35 U/mL), respectively. The rate of posi-
tive CA-125 expression in HG-SOC tissues was 91.6%.
Among all the related clinic characteristics that were
included in the univariate analysis of MDACC patients,
the nadir and baseline CA-125 level was a predictor of
PFS and OS (p < 0.01 for all values). Likewise, the de-
creasing CA-125 kinetics during primary treatment and
neoadjuvant chemotherapy predicted the PFS (p = 0.01
and p = 0.02, respectively) but not the OS (p = 0.22 and
p = 0.10, respectively), as described in Table 2. The
nadir CA-125 level was an independent predictor of
PFS and OS (p < 0.01 for both). However, the same
does not apply to the baseline CA-125 level, decreasing
kinetics, and neoadjuvant chemotherapy, as described
in Table 3.s in HG-SOCs
OS (OR, 95% CI)
JICR MDACC JICR
reference) 1.00 (reference) 1.00 (reference)
0.54–4.19) 1.24 (0.40–3.98) 1.53 (0.63–4.24)
1.61–8.93) 2.28 (1.14–8.65) 3.56 (2.02–8.27)
2.52–11.05) 3.77 (2.08–10.24) 5.13 (2.72–12.27)
reference) 1.00 (reference) 1.00 (reference)
1.47–2.73) 1.73 (1.26–2.49) 2.01 (1.55–2.47)
reference) 1.00 (reference) 1.00 (reference)
4.50–17.87) 6.24 (3.19–16.39) 7.35 (3.72–14.08)
reference) 1.00 (reference) 1.00 (reference)
1.19–1.42) 1.26 (0.36–6.22) 1.17 (0.75–1.93)
reference) 1.00 (reference) 1.00 (reference)
0.86–1.40) 1.21 (0.38–4.77) 1.13(0.74–1.86)
reference) 1.00 (reference) 1.00 (reference)
1.14–1.92) 1.10 (0.56–2.84) 1.02 (0.65–2.85)
0.98–1.02) 1.00 (0.97–1.03) 1.00 (0.97–1.03)
0.98–1.01) 1.01 (0.98–1.02) 1.01 (0.99–1.02)
1.00–1.03) 1.03 (1.01–1.06) 1.03 (1.00–1.05)
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level for predicting OS and PFS durations in HG-
SOCs from JICR. The nadir CA-125 level remained
an independent predictor of PFS and OS (p < 0.01
for both). However, the same cannot be said for the
baseline CA-125 level, decreasing kinetics, and
neoadjuvant chemotherapy, as described in Tables 2
and 3.Nadir CA-125 level can predict prognosis of EOC
Patients with a nadir CA-125 level lower than or equal
to the median level (10 U/mL) had longer OS and PFS
than those with levels higher than 10 U/mL in MDACC
patients (p = 0.01 for both), as shown in Figure 1A and
1C, respectively. Meanwhile, Figure 1B and 1D show
that a lower nadir CA-125 level in the JICR cases was
associated with longer OS and PFS of HG-SOC (p = 0.04
for both).Figure 1 Nadir CA-125 level is associated with OS (A, B) and PFS (C, DWe found a baseline CA-125 level lower than 800 U/mL
was associated with longer PFS in the MDACC and
JICR cases (p = 0.03 and p = 0.04, respectively). However,
the same does not apply to the OS durations, as shown
in Figure 2. Notably, the nadir CA-125 level (p < 0.01),
but not the CA-125 level at relapse (p = 0.12), was an
independent OS indicator in the ovarian group from
MDACC, as revealed by the multivariate regression
analysis in Table 3.Nadir CA-125 cannot predict residual tumors in HG-SOCs
Among the CCR HG-SOCs from MDACC that under-
went a second-look, the pCR cases had longer OS
(p < 0.01) and PFS (p = 0.01) than those with residual
lesions, as shown in Figure 3.
To evaluate the potential correlation between the nadir
CA-125 level and the residual tumors in second-look
surgery, we performed binary logistic regression analysis) in HG-SOCs from the MDACC (A, C) and JICR (B, D) groups.
Figure 2 Baseline CA-125 level is associated with PFS in HG-SOCs from the MDACC (A) and JICR (B) groups.
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were found (p = 0.09; Table 4).
Discussion
The use of higher nadir CA-125 levels below the upper
normal limit to indicate poorer prognosis in CCR EOC
patients and the consequent need for further consolidation
or maintenance therapy has been a long-standing issue
[20]. The primary therapy of EOC patients commonly
ends after standard treatment, most including cytore-
duction surgery and adjuvant chemotherapy. Several
studies have suggested that the CA-125 level may be
used to stratify high-risk recurrent patients [13]. As het-
erogeneous groups, different EOC pathological types
present distinct clinical characteristics that indicate pa-
tient prognosis, including the CA-125 level. The use ofFigure 3 Patients who underwent pCR have longer OS (A) and PFS (Ba uniform reference value or interval may not be appro-
priate for estimating the prognosis of all types of EOCs.
The inconsistent results from different studies may be
also partially attributed to the unspecific use of CA-125
for all EOC types.
In the present study, we found that the nadir CA-125
level is an independent prognosis indicator of HG-SOC.
The OS and PFS varied between the subgroups with me-
dian nadir serum CA-125 levels (10 U/mL). Although
the CA-125 level has been associated with EOC progno-
sis, no consensus has been reached regarding a fixed
cut-off value for the nadir CA-125 level when predicting
prognosis. Several studies have suggested a CA-125
level based on the observed median value [21]. Others
used an arbitrary cut-off value, such as 10 U/mL and
12 U/mL, or an interval for the stratification of cohorts,) than other HG-SOCs from the MDACC group.
Table 4 Logistic regression of residual tumor-associated
factors in HG-SOCs
Factors Univariate Multivariate
Exp(β) Sig Exp(β) Sig
Age 1.01 0.15 1.30 0.42
Ascites 1.47 0.02 2.22 0.24
Stage 2.52 0.00 1.96 0.04
Nadir CA-125 1.05 0.01 1.02 0.09
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However, the median and arbitrary cut-off values
vary among the different EOC subtypes. The median
nadir CA-125 level of HG-SOC was 10 U/mL in both
MDACC and JICR populations. Furthermore, the OS
and PFS were longer for the pCR subgroup than for pa-
tients with residual tumors confirmed by second-look
surgery; however, this issue remains controversial [25-30].
Although the serum CA-125 level is known to reflect the
tumor burden, our results did not confirm its role in de-
termining the minimal degree of residual disease [31-33].
Given that only 80 of 616 patients (13.0%) were in-
cluded in the analysis, the validity of our findings for
the population with HG-SOC is unclear.
Based on the consideration that CA-125 can predict
prognosis, the conventional concept of the CCR as the
end of primary treatment needs further evaluation [12].
Identifying the best therapy and defining the patient
groups that might best benefit from a consolidation or
maintenance strategy are equally challenging, given that
the present strategy assumes that all HG-SOC cases will
recur. Thus, clinicians will be able to advise patients
who achieve CCR after primary chemotherapy by deter-
mining the therapeutic ratio of possible harm versus
potential benefit for an individual patient. The same re-
cruitment standards and analysis methods were used to
study HG-SOC from two different cancer centers. Thus,
the bias in this study was reduced to a certain extent.
The nadir CA-125 level associated with prognosis does
not reflect the presence of residual tumors. CA-125 is in-
effective for minor tumor burdens.
The baseline CA-125 is found a significant but not
independent variables. Actually, higher decline rate of
CA-125 means higher baseline level in CCR ovarian
cancer with negative CA-125 level (<35 U/mL). CA-125
level >10 U/mL meanwhile decreasing more than 97.6%
decreasing kinetics <1/32) indicates poorer OS and PFS,
in another words, baseline CA-125 level more than or
equal to 424-1484 U/ml indicate more relapse and
death. Our results suggest that for patients even achieved
CCR, we need pay more attention to those with high ini-
tial CA-125 level.
This retrospective analysis has several limitations.
First, given the long survival durations of our studypopulation from the two institutions, the heterogeneity
of treatment strategies used throughout the 28-year
study period, the emergence of new treatment regimes,
such as paclitaxel-based chemotherapy and molecular
target therapy [34,35], the influence of the therapy
and evaluate strategy is difficult to exclude. Second,
we focused on the nadir CA-125 level in HG-SOCs.
However, 8.4% negative tissue expression and 11.2% nor-
mal serum level were observed for CA-125.
Our study supports the emerging evidence showing
that the nadir CA-125 level in HG-SOCs may be an in-
dependent prognostic factor for both OS and PFS. The
application of CA-125 strata for future prospective trials
of HG-SOC consolidation or maintenance should be
considered.
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